Key Events This Week
Jan 6: Death Cross formation signals potential bearish trend
Jan 7: Technical momentum shifts amid mixed market signals
Jan 9: Week closes at Rs.257.50 (+0.98%) outperforming Sensex
Feb 03
BSE+NSE Vol: 3.89 lacs

Dishman Carbogen Amcis Ltd recorded a robust intraday performance on 3 Feb 2026, surging 7.31% to touch a day’s high of Rs 233.5, significantly outperforming the broader market and its sector peers.
Read full news article
Dishman Carbogen Amcis Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 12 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 24 January 2026, providing investors with the most up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read full news article
Dishman Carbogen Amcis Ltd, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, prompting a downgrade in its Mojo Grade from Hold to Sell as of 12 Jan 2026. The stock’s recent price action and technical indicators signal increasing bearishness, reflecting investor caution amid broader market pressures and sector-specific challenges.
Read full news article
Jan 6: Death Cross formation signals potential bearish trend
Jan 7: Technical momentum shifts amid mixed market signals
Jan 9: Week closes at Rs.257.50 (+0.98%) outperforming Sensex

Dishman Carbogen Amcis Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 05 Jan 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 10 January 2026, providing investors with an up-to-date perspective on the stock’s fundamentals, valuation, financial trends, and technical outlook.
Read full news article
Dishman Carbogen Amcis Ltd has experienced a notable shift in its technical momentum, moving from a mildly bullish to a mildly bearish stance across key indicators. Despite a modest day gain of 0.45%, the stock’s technical parameters suggest a cautious outlook for investors amid mixed signals from MACD, RSI, moving averages, and other momentum oscillators.
Read full news article
Dishman Carbogen Amcis Ltd has recently formed a Death Cross, a significant technical indicator where the 50-day moving average crosses below the 200-day moving average. This development often signals a shift towards a bearish trend, suggesting potential long-term weakness and a deterioration in the stock’s momentum.
Read full news article
29 Dec 2025: Stock opens at Rs.250.00, closes at Rs.245.70 (-1.72%)
30 Dec 2025: Downgrade to Sell rating; stock closes at Rs.243.50 (-0.90%)
31 Dec 2025: Technical momentum shifts; stock rebounds to Rs.247.90 (+1.81%)
1 Jan 2026: Mildly bullish technical stance; stock surges to Rs.256.95 (+3.65%)
2 Jan 2026: Slight pullback; stock closes at Rs.255.00 (-0.76%)

Dishman Carbogen Amcis Ltd, a key player in the Pharmaceuticals & Biotechnology sector, has exhibited a nuanced shift in its technical momentum as it transitions from a sideways trend to a mildly bullish stance. Despite a recent downgrade in its Mojo Grade to Sell, the stock’s price action and technical indicators reveal a complex interplay of bullish and bearish signals that investors should carefully consider.
Read full news articleThe Company has arranged Conference Call with Investors on Wednesday 4th February 2026 at 15:00 hrs. (IST) to discuss the financial result and performance of the Company for the third quarter ended on 31st December 2025. The details of Conference Call are attached herewith.
Dishman Carbogen Amcis Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/02/2026 inter alia to consider and approve Un-Audited Financial Results of the Company for the third quarter ended on 31st December 2025
Pls. find attached herewith intimation of allotment of 5000 NCDs.
(03 Feb 2026)
Dishman Carbogen Amcis Ltd has declared 10% dividend, ex-date: 12 Sep 19
No Splits history available
No Bonus history available
No Rights history available